Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Development of Collagenase Polymeric nanocapsules as Therapeutics

Descrizione del progetto

Trattamento della sclerodermia con nanocapsule di collagenasi

La sclerodermia, o sclerosi sistemica, è una malattia reumatica autoimmune cronica del tessuto connettivo. L’indurimento della pelle è la manifestazione più visibile della malattia, associata a un accumulo anomalo di collagene. Il trattamento prevede l’utilizzo di enzimi proteolitici quali la collagenasi, in grado di assimilare le fibre di collagene. Tuttavia, la natura labile della collagenasi compromette la sua attività nel corpo umano. L’obiettivo del progetto DECOMPACT, finanziato dall’UE, è sviluppare e commercializzare un trattamento migliore per la sclerodermia che implica l’uso di nanocapsule di collagenasi polimerica che rilasciano enzimi incapsulati protetti dopo irradiazione UVA. I nuovi nanodispositivi combineranno la capacità dell’enzima proteolitico di degradare il collagene con gli effetti immunosoppressivi e antinfiammatori degli UVA.

Obiettivo

“Developments of Collagenase Polymeric nanocapsules as Therapeutics (DECOMPACT)”. The goal of this proof of concept project is the development and commercialization of a novel treatment to scleroderma. Scleroderma is a fibrotic disease with a significant incidence in the population and is characterized by an abnormal accumulation of collagen. Treatment of this disease involves the use of proteolytic enzymes, as collagenase, able to digest collagen fibers. However, the labile nature of collagenase compromises its activity in the human body. DECOMPACT purposes the development of polymeric-collagenase nanocapsules that protect the housed enzymes against external insults and are able to release them by UVA irradiation exposition. UVA irradiation has been selected as trigger release stimuli due to its capacity to induce both anti-inflammatory, immunosuppressive effects and to enhance collagenase production in situ. These novel stimuli-responsive nanodevices would combine the ability of the proteolytic enzyme to degrade collagen with the immunosuppressant and anti-inflammatory effects of UVA. The methodology to obtain the system is based on previous results achieved in the context of the Advance Grant ERC-2015-AdG Proposal No.694160 VERDI. The work plan involves the synthesis of a library of UVA-sensitive cross-linkers which form the nanodevice, studies of UVA-responsive and evaluation of collagen digestion ability both in vitro employing 3D collagen matrices with skin cells embedded and in vivo using a scleroderma mouse model. This project supposes an important innovation respect to conventional treatments and could provide important social-economic benefits to the society. Finally, DECOMPACT embraces a work plan considering the commercialization steps which are required in order to place this technology in the market. The work team involved in this project includes specialized professionals in nanotechnology and medical doctors expert in fibrotic diseases.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2018-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSIDAD COMPLUTENSE DE MADRID
Contributo netto dell'UE
€ 149 611,00
Indirizzo
AVENIDA DE SENECA 2
28040 Madrid
Spagna
Regione
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 149 611,00

Beneficiari (1)